- Home
- AGEN vs FOSL Comparison
AGEN vs FOSL Comparison
Compare AGEN & FOSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGEN
- FOSL
- Stock Information
- Founded
- AGEN 1994
- FOSL 1984
- Country
- AGEN United States
- FOSL United States
- Employees
- AGEN N/A
- FOSL N/A
- Industry
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- FOSL Consumer Specialties
- Sector
- AGEN Health Care
- FOSL Consumer Discretionary
- Exchange
- AGEN Nasdaq
- FOSL Nasdaq
- Market Cap
- AGEN 96.2M
- FOSL 100.0M
- IPO Year
- AGEN 2000
- FOSL 1993
- Fundamental
- Price
- AGEN $3.32
- FOSL $1.54
- Analyst Decision
- AGEN Buy
- FOSL
- Analyst Count
- AGEN 3
- FOSL 0
- Target Price
- AGEN $10.50
- FOSL N/A
- AVG Volume (30 Days)
- AGEN 357.6K
- FOSL 223.7K
- Earning Date
- AGEN 03-13-2025
- FOSL 03-12-2025
- Dividend Yield
- AGEN N/A
- FOSL N/A
- EPS Growth
- AGEN N/A
- FOSL N/A
- EPS
- AGEN N/A
- FOSL N/A
- Revenue
- AGEN $160,427,000.00
- FOSL $1,223,954,000.00
- Revenue This Year
- AGEN N/A
- FOSL N/A
- Revenue Next Year
- AGEN $26.02
- FOSL N/A
- P/E Ratio
- AGEN N/A
- FOSL N/A
- Revenue Growth
- AGEN 59.00
- FOSL N/A
- 52 Week Low
- AGEN $2.50
- FOSL $0.75
- 52 Week High
- AGEN $19.69
- FOSL $2.61
- Technical
- Relative Strength Index (RSI)
- AGEN 45.96
- FOSL 39.03
- Support Level
- AGEN $3.09
- FOSL $1.60
- Resistance Level
- AGEN $3.68
- FOSL $1.80
- Average True Range (ATR)
- AGEN 0.25
- FOSL 0.11
- MACD
- AGEN -0.03
- FOSL -0.01
- Stochastic Oscillator
- AGEN 23.00
- FOSL 5.71
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
About FOSL Fossil Group Inc.
Fossil Group Inc is a design, innovation and distribution company in consumer fashion accessories. The products include traditional watches, smartwatches, jewelry, handbags, small leather goods, belts and sunglasses. The reportable segments are comprised of 1) Americas segment includes sales in Canada, Latin America and the United States. 2) Europe segment includes sales in European countries, the Middle East and Africa. 3) Asia segment includes sales in Australia, China, India, Indonesia, Japan, Malaysia, New Zealand, Singapore, South Korea and Thailand. Each reportable operating segment includes sales to wholesale and distributor customers, and sales through Company-owned retail stores and e-commerce activities based on the location of the selling entity.